CD8A and neoplasm: Previous research has found that BRAFi/MEKi acquired resistance was associated with the depletion of CD8+ T cells in the tumor microenvironment, and BRAFi/MEKi resistance could mediate cross-resistance to anti-PD-1 immunotherapy (Hugo et al., 2015; Hugo et al., 2017).